Vanguard Capital Management
ARTV

Vanguard Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Vanguard Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.52M Buy
981,815
+774,129
+373% +$7.05M ﹤0.01% 2844
2026
Q1 		$1.34M Buy
+207,686
New +$1.03M ﹤0.01% 3487

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management's ARTV Position: Q2 2026 in Review

Vanguard Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 373% in Q2 2026, buying an estimated $7.05M and bringing the position to 981,815 shares worth $9.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Vanguard Capital Management first reported a position in ARTV in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Vanguard Capital Management held 981,815 shares of Artiva Biotherapeutics worth $9.52M as of Q2 2026.
  • Vanguard Capital Management bought 774,129 Artiva Biotherapeutics shares in Q2 2026, an estimated $7.05M.
  • Artiva Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2844 holding.
  • Vanguard Capital Management first reported a position in Artiva Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.